Ubiquigent enables the discovery and development of novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need.
Founded 13 years ago, the Company has an unrivalled track record and unique range of specialist services focused on the exploitation of the DUB enzymes and ubiquitin-proteasome system (UPS).
Ubiquigent is the partner chosen by many leading industry and academic organisations for their drug discovery programmes spanning the development of DUB inhibitors and modulators in the fields of protein degradation, stabilisation, and homeostasis.
Ubiquigent has an internal pipeline of drug discovery programmes and is developing a strong IP portfolio encompassing DUB inhibitors, DUB-targeting Proteolysis Targeting Chimeras (PROTACs) and DUB-Targeting Chimeras (DUBTACs) for subsequent commercialisation via partnerships and out-licensing agreements.
The Company benefits from high calibre backing, including from IP Group PLC, Scottish Enterprise, the UK Medical Research Council (MRC) and the University of Dundee.
Ubiquigent staff have a wealth of scientific experience, technological competencies and commercial expertise, gained from within academia, the life science research reagents and services sector, and the pharmaceutical industry, that enables the Company to offer a level of understanding and service to its customers and clients worldwide that few companies may match.
Based in a state-of-the-art facility located near the University of Dundee, it sits at the centre of a range of highly relevant additional scientific expertise and capabilities.